Publications by authors named "Kimberley Meredith"
Article Synopsis
- The analysis aimed to evaluate the clinical and economic effects of urine albumin-to-creatinine ratio (UACR) testing combined with estimated glomerular filtration rate testing for chronic kidney disease in non-diabetic Japanese patients compared to no testing and urine protein-creatinine ratio (UPCR) testing.
- An economic model assessed the long-term impacts of UACR testing, focusing on costs, health benefits like reduced need for dialysis and cardiovascular events, and overall quality of life improvements.
- Results indicated that repeated UACR testing is cost-effective relative to both no urine testing and UPCR testing, showing significant health-economic value for the non-diabetic Japanese population.
Aims/introduction: This analysis seeks to evaluate the cost-effectiveness of urine albumin-to-creatinine ratio testing compared with urine protein-creatinine ratio testing and no urine testing for the identification of kidney damage in individuals with type 2 diabetes who have, or are at risk of, chronic kidney disease in Japan.
Materials And Methods: A health-economic model estimated the clinical and economic consequences of different tests to evaluate kidney damage in line with Japanese guidelines, taking a Japanese healthcare perspective. Differences in the diagnostic performance of tests were considered by the integration of real-world Japanese data.
Background: Regular monitoring is required to ensure that patients who have, or are at risk of, chronic kidney disease (CKD) receive appropriate management. Guidelines recommend regular testing of estimated glomerular filtration rate (GFR) and albuminuria. However, evidence suggests that albuminuria testing rates, specifically urine albumin-to-creatinine ratio (UACR), are suboptimal.
View Article and Find Full Text PDFEstimated health economic impact of conducting urine albumin-to-creatinine ratio testing alongside estimated glomerular filtration rate testing in the early stages of chronic kidney disease in patients with type 2 diabetes.
J Med Econ
November 2023
Aim: To estimate the health economic impact of undertaking urine albumin-to-creatinine ratio (UACR) testing versus no UACR testing in early stages of chronic kidney disease (CKD) progression in patients with type 2 diabetes (T2D).
Methods: An economic model, taking a UK healthcare system perspective, estimated the impact of UACR testing on additional costs, clinical benefits measured as prevented dialyses and cardiovascular-related deaths, life years gained (LYg), LYg before kidney failure, and incremental cost-effectiveness ratio (ICER). Sixteen of the 18 Kidney Disease: Improving Global Outcomes (KDIGO) heatmap categories were considered separately, and grouped in health states according to CKD risk.